title: Accelerated hyperfractionated irradiation with concomitant boost for stage II laryngeal cancer and locally advanced head and neck cancer.
abstract: OBJECTIVE
  This study was conducted to evaluate the efficacy and feasibility of our accelerated hyperfractionation with concomitant boost for stage II laryngeal cancer and stages III-IVb locally advanced head and neck cancer.
  
  
  METHODS
  From January 2000 to October 2001, eight patients with AJCC 1998 stage II laryngeal cancer and 11 patients with AJCC 1998 stages III-IVb locally advanced head and neck cancer underwent accelerated hyperfractionated radiation therapy. For the stage II laryngeal cancer, radiation was delivered at a 2.0 Gy fraction a day, 5 fractions per week for the first 3 weeks, then 2 fractions (1.8 and 1.2 Gy) a day, 5 times a week for 2.5 weeks, with total dose of 69 Gy. For stages III-IVb head and neck cancer, radiation was given at a 1.8 Gy fraction a day, 5 fractions per week for 6 weeks and a boost was added up to 70.5 Gy with 1.5 Gy as a second daily fraction during the last 2.2 weeks. Among the patients, 16 (84%) received concomitant chemotherapy, mainly with low-dose carboplatin. Acute toxicity based on RTOG criteria and tumor response at 1 month post-treatment were estimated as initial effects.
  
  
  RESULTS
  The overall response rate was 100% in patients with stage II laryngeal cancer and 91% in patients with stages III and IVb head and neck cancer. The incidence of grade 3 or worse acute effects was 47%. Eighteen patients (95%) completed radiation therapy without interruption related to acute side effects, while one had prolongation of the treatment for more than 1 week because of neutropenia.
  
  
  CONCLUSIONS
  Our results demonstrated that accelerated hyperfractionation, mostly combined with concomitant chemotherapy, had a good overall response rate with acceptable toxicity in stage II laryngeal cancers and stages III-IVb head and neck tumors.
authors.affiliation: Department of Radiology, Osaka City University Graduate School of Medicine, Osaka, Japan. afbxw706@oct.zaq.ne.jp
authors.forename: Kenntaro
authors.initials: K
authors.lastname: Ishii
authors.forename: Mari
authors.initials: M
authors.lastname: Tashiro
authors.forename: Masako
authors.initials: M
authors.lastname: Hosono
authors.forename: Haruyuki
authors.initials: H
authors.lastname: Fukuda
authors.forename: Yoshie
authors.initials: Y
authors.lastname: Takada
authors.forename: Satoko
authors.initials: S
authors.lastname: Kondo
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Inoue
authors.forename: Hiroyoshi
authors.initials: H
authors.lastname: Iguchi
authors.forename: Makoto
authors.initials: M
authors.lastname: Kusuki
authors.forename: Hideo
authors.initials: H
authors.lastname: Yamane
mesh_terms: D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000473:pathology / Q000532:radiotherapy*; D019583:Dose Fractionation, Radiation; D004334:Drug Administration Schedule; D064420:Drug-Related Side Effects and Adverse Reactions; D005260:Female; D006258:Head and Neck Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D006801:Humans; D007822:Laryngeal Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011879:Radiotherapy Dosage; D016019:Survival Analysis; D016896:Treatment Outcome